INTRODUCTION
Pharmacologic treatment of type 2 diabetes (T2DM) to improve glycemic control, control hypertension, and reduce blood lipid concentrations reduces the occurrence and progression of diabetes complications (1) (2) (3) (4) (5) (6) . High concentrations of the inflammatory marker C-reactive protein (CRP) are associated with greater risks of cardiovascular disease (CVD) and diabetes in persons without diabetes (7) and a greater risk of CVD in persons with diabetes (8) . Serum CRP can be reduced in T2DM patients with the use of statins (9, 10) or thiazolidinediones (11) and, in persons with impaired glucose tolerance, with the use of metformin or weight reduction and exercise (12) . However, the ability of dietary management to influence the outcome of diabetes is not clear.
Although almost everyone would agree that diet is the cornerstone of diabetes therapy, there is marked disagreement about what kind of dietary advice is best, particularly with respect to dietary carbohydrate. Low-fat and high-carbohydrate (high-CHO) diets may help maintain body weight (13) and insulin sensitivity (14) , but they may increase CVD risk by increasing blood glucose, insulin, and triacylglycerol concentrations and reducing HDL-cholesterol concentrations (15, 16) . The role of the glycemic index (GI), a classification of the glycemic effect of high-carbohydrate foods, is controversial (17, 18) . Resolution of these issues requires high-quality evidence. However, a Cochrane review concluded that, because of methodologic flaws, no high-quality data on the efficacy of dietary treatment in T2DM exist (19) . In addition, most existing data are from short-term (4 -6-wk) studies, whose results may be misleading because of physiologic adaptation. For example, the reduction in the ratio of total to HDL cholesterol (total:HDL cholesterol) induced by a low-CHO and high-monounsaturated fatty acid diet in T2DM patients may disappear by 6 mo (20) .
Thus, because of the poor quality of the currently available evidence and the controversy about dietary carbohydrates in the management of T2DM, we conducted a long-term, multicenter, randomized controlled trial with the aim of comparing the effects of altering the source of carbohydrate with the effects of reducing the amount of dietary carbohydrate on the primary endpoint of glycemic control assessed by glycated hemoglobin (HbA 1c ) and on secondary endpoints of blood glucose, lipids, and CRP in patients with T2DM managed by diet alone.
SUBJECTS AND METHODS

Subjects
Men or nonpregnant women with T2DM [fasting plasma glucose ͧ 7.0 mmol/L or plasma glucose ͧ11.1 mmol/L 2 h after a 75-g oral-glucose-tolerance test (OGTT) on ͧ1 occasion within 2 mo of randomization] that was managed by diet alone were recruited. Subjects were 35-75 y old and had HbA 1c ͨ130% of the upper limit of normal and a body mass index (BMI; in kg/m 2 ) of 24 to 40. Exclusion criteria were the use of insulin or any hypoglycemic or antihyperglycemic medication, stroke, myocardial infarction or major surgery within 6 mo of randomization, serum triacylglycerol concentrations 10 mmol/L, any major debilitating disorder, any condition or drug likely to alter nutrient absorption, use of oral steroids, substance or alcohol abuse, allergy or intolerance to 1 of the study key foods, and expectation of being on vacation and unable to take study foods for 8 wk in a row or a total of 12 wk.
Written informed consent was obtained from all subjects. The procedures followed were in accordance with the ethical standards of each institution involved, and approval was obtained from the relevant ethics review committee on human subjects. The trial was registered on the Current Controlled Trials register (ISRCTN Reg. no. ISRCTN81151522. Internet: http://www. controlled-trials.com/ISRCTN81151522).
Baseline period
After eligibility was determined, subjects were instructed how to record all foods and drinks consumed during 2 typical weekdays and 1 weekend day (3-d food record). After the food record had been completed, subjects underwent a baseline 75-g OGTT, and the food record was reviewed by a registered dietitian who provided dietary advice with the aim of a diet containing Ȃ55% of energy as carbohydrate, Ȃ15% of energy as protein, and Ȃ30% of energy as fat and with ͨ10% saturated fatty acids (SFAs), ͨ10% polyunsaturated fatty acids, and the remainder as monounsaturated fatty acids (MUFAs) (21) . Two weeks later, the baseline (high-GI) breakfast test meal profile was performed, and subjects were randomly assigned to receive one of the following diets for 1 y: 1) high-CHO and high-GI (the high-GI diet), 2) high-CHO and low-GI (the low-GI diet), or 3) low-CHO and high-MUFA (the low-CHO diet).
Randomization and concealment
Subjects, stratified by center, were randomly assigned to 1 of the 3 diets with the use of blocks of various sizes to enhance allocation concealment (22, 23) . Treatment assignments were sealed in sequentially numbered opaque envelopes kept by a person not involved with the study, and they were assigned to subjects in order on the day they attended for the baseline metabolic profile. Randomization (generated by computer with the random seed chosen from a table of random numbers) and the preparation of the sealed envelopes were done by one of us (ALG).
Dietary intervention
The dietary intervention called for in the study protocol was for subjects to consume specific key foods, which, by themselves, would result in the desired changes in nutrient intake. Subjects in each diet group could choose from 16 -21 key foods ( Table 1) , which were provided free of charge. Choices could vary throughout the study period, and intake was recorded daily in key-food diaries. For the high-and low-GI diets, the key foods were starchy carbohydrates whose GI we had determined (24 -29) . The amount prescribed was such that their carbohydrates provided 20 -25% of the energy requirement estimated by using the tables of the Lipid Research Clinics (30) to which 300 kcal/d was added for exercise (31) and from which 500 kcal/d was subtracted if the subject wished to lose weight. We expected this intervention to result in a GI difference of Ȃ10 between the high-GI and low-GI diets (32) . For the low-CHO diet, key foods consisted of olive or canola oils or spreads, nuts, and other foods low in SFAs and high in MUFAs and known to be associated with reduced risks of diabetes and CVD (33) (34) (35) or known to reduce blood lipids (16, 36, 37) . These foods replaced carbohydrate foods normally consumed and were prescribed in amounts sufficient to raise total fat intake by Ȃ10%.
Subjects received individualized advice from a registered dietitian at each visit. General advice on following a heart-healthy diet was provided to all subjects. Each subject had an individualized education session with the dietitian about the dietary intervention he or she was to follow on the day of the first metabolic profile (the day of randomization). This session lasted for 30 -60 min, during which time the previously collected food records were reviewed and the study protocol explained. For subjects randomly assigned to the high-GI diet, the advice focused on following a healthy low-fat diet and avoiding low-GI foods. Subjects randomly assigned to the low-GI diet were given lowfat diet advice along with suggestions about to how to exchange high-GI foods for low-GI foods. Subjects randomly assigned to the low-CHO diet were given advice about how to reduce SFA intake and how to exchange carbohydrate-rich foods for the study key foods high in MUFAs. All subjects were given a list of the key foods for their respective study diet, and the list indicated the number of servings they were to consume each day. Subjects were advised on how to incorporate the key foods into their diet in exchange for others so as to avoid weight gain.
Subjects were seen 2 and 4 wk after randomization and then every 4 wk for weighing, review of key-food diaries, and pick-up of supplies of key foods. During each 30-min visit, dietitians provided individualized dietary advice and discussed any challenges that subjects encountered in following the study protocol and their solutions. Three-day food records were recorded twice during the run-in period and at 1, 3, 6, 9, and 12 mo after randomization.
Fasting blood samples and oral-glucose-tolerance tests
Blood samples were obtained after 10 -14-h overnight fasts at baseline and at 1, 3, 6, 9, and 12 mo after randomization. Subjects underwent 75-g OGTTs at baseline and 3, 6, and 12 mo after randomization with blood samples for plasma glucose and insulin taken fasting and at 30, 60, and 120 min after the subjects started to consume the glucose.
Breakfast profile test
Subjects underwent breakfast profile tests at baseline and 2 wk after the final OGTT (subjects continued to consume their study diets between the final OGTT and the final breakfast profile). At baseline all subjects received a breakfast meal of normal foods reflective of the high-GI diet. At the end of the study, half of the subjects were randomly assigned to receive a breakfast meal that reflected the composition of the diet they had been consuming during the study (ie, high-GI, low-GI, or low-CHO diet); the other half of the subjects received the same breakfast as at baseline. We report here the results of the breakfast profiles for the subjects whose test meals at the end of the study reflected the diet they consumed during the study (ie, all subjects following the high-GI diet and 50% of the subjects following the low-GI or low-CHO diet). Breakfast-profile tests were performed after 10 -12-h overnight fasts; fasting blood samples were taken, and additional blood samples were taken at hourly intervals for 4 h after the subjects started to consume the breakfast test meal. 
Treatment failure
If HbA 1c was 140% of the upper limit of normal (ie, 5.8%) regardless of the fasting plasma glucose (FPG) concentration, or if FPG was 10.0 mmol/L and HbA 1c was 130% of the upper limit of normal on 2 consecutive occasions, subjects were considered to have failed the treatment, and they were withdrawn from the study and treated with an oral agent or insulin of the physician's choice.
Concomitant medications
Doses of lipid-lowering drugs were adjusted during the run-in period for optimum control, and then they were kept constant unless a change was required for clinical reasons. Subjects whose dose of statin medication changed during the study (n ҃ 15) were excluded from the analysis of blood lipids, lipoproteins, and CRP.
Laboratory procedures
Blood samples were analyzed centrally. We measured HbA 1c with HPLC (Diamat HPLC; Bio-Rad Laboratories Ltd, Mississauga, Canada), plasma glucose by using a hexokinase method, insulin by using an electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany), and we measured free fatty acids (FFAs) enzymatically (Wako Chemical Industries, Dallas, TX). Serum cholesterol, triacylglycerol, apolipoprotein (apo) A-I, and apo B were measured as previously described (31); HDL was measured after the precipitation of non-HDL cholesterol with the use of dextran sulfate magnesium chloride (38) , and LDL cholesterol was calculated. CRP was analyzed by using nephelometry (Behring BN-100; DadeBehring, Mississauga, Canada).
Power analysis
To allow detection of a difference of 0.36%/y in the rate of change of HbA 1c between the low-CHO and low-GI diets with 80% probability and a 2-tailed P ͨ 0.05, the estimated sample size was 42/group. With an allowance for a 20% dropout rate, we planned to randomly assign 168 subjects to the 3 treatment groups.
Statistical analysis
The nutrient composition of test meals and diets was assessed by using an in-house program with a nutrient database based on the Canadian Nutrient File and with values for GI added as described previously (39) . The term "carbohydrate" refers to available carbohydrate, defined as total carbohydrate minus dietary fiber. Glycemic load (GL) was calculated as the sum of GI ҂ g for each food in the diet, where g represents grams carbohydrate. The GI of test meals and diets was calculated as GL/G, where G is the amount of carbohydrate in the entire meal or diet. GL values of the diets were adjusted for energy by using the residuals method. We calculated incremental areas under the curve (AUC), ignoring the area beneath the fasting value, as described previously (40) .
Longitudinal analyses of primary and secondary outcomes were carried out by using a general linear mixed model in SAS PROC MIXED software [version 8.2 for Unix; SAS Institute, Cary, NC (41) ]. The correlation structure between measurements from the same subject was unspecified and estimated from the data. Time was treated as a regression variable; nonlinearity in change over time was modeled by polynomials up to degree 3. Model covariates included the baseline value and any of age, BMI, sex, and center that correlated significantly with the response variable. Models for 2-h glucose and insulin included the fasting value as a covariate. Outcomes were modeled for time points when subjects were under treatment. Diet ҂ time interactions represent differences in the shape of the response profile over time by diet for these time points. Main effects of diet indicate differences among the diet groups between baseline and the first measurement taken during treatment. Data on those who dropped out because of treatment failure were retained in the model up to and including the point at which they were declared to have failed treatment, so the missing values for the subjects can be considered to be missing at random. All other missing observations (eg, those missing because of missed appointments or adverse events not related the study treatments) can be considered to be missing completely at random.
Analysis of CRP, fasting insulin, and FFAs was carried out on the natural logarithm of the values to improve the symmetry and homoscedasticity of the distributions. Plots of these variables display the estimated percentage change from baseline. Data in tables are displayed in the original scale of measurement.
For the breakfast profiles, the significance of differences in plasma glucose increments and AUC from baseline values were assessed by using a paired t test. The significance of differences in glucose increments and AUC between baseline and 1 y were compared across the different diets by using one-factor analysis of variance (ANOVA) with Tukey's test used to control for multiple comparisons. Differences were considered significant if 2-tailed P values were 0.05.
RESULTS
One hundred sixty-two subjects were randomly assigned to receive the high-GI (n ҃ 52), low-GI (n ҃ 56), or low-CHO (n ҃ 54) diet (Figure 1) . At baseline, 77 (48%) subjects were taking an angiotensin-converting enzyme inhibitor (n ҃ 35), a diuretic (n ҃ 26), a calcium channel blocker (n ҃ 19), an angiotensinreceptor blocker (n ҃ 17), or a ␤-blocker (n ҃ 15) or an ␣-blocker (n ҃ 5) (or both); 47 of the subjects were taking a single agent and 30 were taking ͧ2 agents. Sixty-nine subjects (43%) were taking lipid-lowering medication; 58 were taking a statin, 4 were taking fibrate and 7 were taking both; in addition, 50 subjects (31%) were taking aspirin. The distribution of medications did not differ significantly between the diet groups. The only significant differences among diet groups at baseline were lower LDL cholesterol in subjects following the high-GI diet than in those following the low-GI diet and lower CRP in those following the low-CHO diet than in those following the high-GI diet ( Table 2) .
Subjects following the high-GI, low-GI, and low-CHO diets were prescribed 9.0 Ȁ 0.4, 7.9 Ȁ 0.3, and 5.2 Ȁ 0.2 servings of key foods/d, respectively. Key-food diaries were obtained from 147 (91%) subjects, and consumption was recorded for 95% of the days of the study. Subjects on the high-GI, low-GI, and low-CHO diets consumed 85 Ȁ 3%, 81 Ȁ 3%, and 106 Ȁ 3%, respectively, of the amount prescribed; the energy intake from key foods with those diets was 611 Ȁ 13, 532 Ȁ 24, and 323 Ȁ 14 kcal/d, representing 33.5 Ȁ 1.6%, 30.2 Ȁ 1.4%, and 16.1 Ȁ 0.6%, respectively, of recorded energy intake.
The 3-d food records showed that fat intake fell from baseline with the high-GI and low-GI diets and increased with the low-CHO diet; approximately two-thirds of the increase in fat with LOW-GI VS LOW-CARBOHYDRATE DIET IN DIABETES the low-CHO diet was accounted for by MUFAs and the remainder was accounted for by polyunsaturated fat ( Table 3) . Intakes of SFAs and cholesterol fell slightly but significantly with all 3 diets. Carbohydrate intake increased from baseline with the high-GI and low-GI diets and decreased with the low-CHO diet. Fiber intake did not change with the high-GI or low-CHO diet, but it increased with the low-GI diet. Diet GI increased with the high-GI diet, fell with the low-GI diet, and did not change with the low-CHO diet; GL increased with the high-GI diet, did not change with the low-GI diet, and decreased with the low-CHO diet.
Glycemic control
HbA 1c rose from Ȃ6.1% at baseline to Ȃ6.3% after 1 y (P 0.0001; Figure 2 ), but there was no significant difference in HbA 1c with the different diets ( Table 4) . HbA 1c tended to fall initially with the low-GI diet (time ҂ diet interaction, P ҃ 0.084; Figure 2 ). There were significant time ҂ diet interactions for FPG (P ҃ 0.041) and plasma glucose 2 h after OGTT (P ҃ 0.010; Figure 2 ). FPG fell initially with the low-GI and low-CHO diets but then rose, so that, by 12 mo, FPG was lowest with the high-GI diet. At 3 mo, 2-h post-OGTT plasma glucose concentrations were Ȃ8% lower with the low-CHO diet than with the other diets; by 12 mo, however, the glucose concentration had risen steadily to a value Ȃ7% greater than that with the low-GI diet (P 0.05; Figure 2 ). There were no significant differences in fasting or 2-h post-OGTT insulin concentrations.
Body weight and blood pressure
There was a main effect of time squared (P ҃ 0.0005) for body weight, which fell over the first 8 wk and then rose steadily over the remainder of the trial (Table 4; Figure 3 ). Although the initial weight loss was mainly seen with the low-GI diet, and the late weight gain was mainly seen with the low-CHO diet, these differences were not significant (diet ҂ time interaction, P ҃ 0.09; main effect of diet, P ҃ 0.062). There was no significant effect of diet, time, or diet ҂ time interaction for systolic blood pressure, but there was a significant diet ҂ time interaction for diastolic blood pressure (Table 4; Figure 3 ).
Blood lipids and lipoproteins
There were no significant effects for total cholesterol or apoB (Table 4 ). With the low-GI diet, mean triacylglycerol was 12% higher, HDL was 4% lower, and the ratio of apoB to apoA was 4% higher than with the low-CHO diet (P 0.05 for all); the high-GI diet values were intermediate. Mean apoA was 4% lower with the low-GI diet than with the high-GI diet (P 0.05); the value with the low-CHO diet was intermediate. There was a significant diet ҂ time interaction for total:HDL cholesterol (P ҃ 0.044; Table 4 ); initially, the total:HDL was 6 -8% lower with the low-CHO diet than with the low-GI diet, but this difference disappeared after 6 mo (Figure 4) .
C-reactive protein
There was a highly significant main effect of diet (P ҃ 0.0078), in which mean CRP with the low-GI diet was 29% less than that with the high-GI diet (P 0.05). The diet ҂ time interaction was nearly significant (P ҃ 0.064); with the low-GI diet, CRP tended to fall throughout the study, reaching a reduction from baseline of 20% by 12 mo. With the high-GI diet, CRP increased acutely by 40% and then stabilized 15-20% above baseline from 3-12 mo. With the low-CHO diet, mean CRP was between the values seen with the high-GI and low-GI diets throughout (Figure 5) . At baseline, 57%, 43%, and 33% of subjects following the high-GI, low-GI, and low-CHO diets, respectively, had CRP ͧ 3 mg/L (NS). After 1 y, the proportion of subjects with CRP ͧ 3 mg/L had increased to 80% with the high-GI diet, decreased to 33% with the low-GI diet, and not changed (33%) with the low-CHO diet (P 0.0001).
Breakfast profile
The GL of the low-GI and low-CHO breakfast test meals taken at the end of the study were 24% less than the GL of the respective high-GI meals taken at baseline, because of a reduction in GI with the low-GI diet and a lower carbohydrate intake with the low-CHO diet ( Table 5) . At the end of the study, the glycemic responses elicited by the high-GI and low-CHO diet breakfast meals did not differ significantly from the response elicited by the high-GI meal at baseline. However, the 1-h glucose increment elicited by the low-GI meal was not only 24% less than baseline (P ҃ 0.04), but also significantly less than the increments seen with the other diets (P 0.05; Figure 6 ). The mean AUC with the low-GI diet was 24% less than baseline (P ҃ 0.008) and less than that seen with the high-GI diet (P ҃ 0.016); the AUC with the low-CHO diet was intermediate. 7 ,13 Significant effects of 7 time squared and 13 time cubed (P 0.01, indicating 1 or 2 inflections of the curve, respectively). 8 Means not given because of significant time ҂ diet interactions; see figures for results. 9 Statistical analysis was performed on log-transformed data. Values are geometric x ; 95% CIs in parentheses.
DISCUSSION
We aimed for this study to provide high-quality evidence for the long-term (1 y) effects of altering the source or amount of dietary carbohydrate in the management of T2DM. The results showed that modest reductions in carbohydrate intake or diet GI for 1 y had no significant effect on HbA 1c concentrations in T2DM patients with optimal glycemic control treated by diet alone. However, significant time ҂ treatment interactions existed for a number of endpoints, which suggests that the longterm effects of changes in dietary carbohydrate on CVD risk factors may not be reflected by the results of studies lasting 6 mo. Moreover, the low-GI diet caused a large, sustained reduction in CRP.
Our results do not agree with meta-analyses showing that low-GI diets reduce HbA 1c or fructosamine in subjects with or without diabetes (18, 42, 43) . The meta-analyses were based largely on studies lasting 3 mo, and it is possible that the effects of a low-GI diet on HbA 1c in T2DM patients are not sustained for 1 y. This possibility is weakly supported by our finding of a nonsignificant trend toward a temporary reduction in HbA 1c with the low-GI diet. However, most T2DM patients in published reports of trials of low-GI diets had HbA 1c 7.5-8.5% at baseline (18) . By contrast our subjects had optimal mean HbA 1c at baseline, ie, 6.1%, which may be more difficult to reduce. In addition, because dietary changes had to be sustained over long period of time, the difference in diet GI here was smaller than that in many short-term studies, and that smaller difference may have contributed to our inability to detect a significant effect of the low-GI diet on HbA 1c . Our results for the low-CHO diet are consistent with the results of shorter-term studies, none of which show any significant effect of a low-CHO and high-MUFA diet on HbA 1c or fructosamine concentrations (16, 44, 45) .
Although HbA 1c did not change significantly, the different diets had distinct effects on glucose metabolism. With the high-GI diet, FPG remained stable throughout the study, whereas, with the low-GI and low-CHO diets, FPG fell initially but then rose to exceed the concentration seen with the high-GI diet by 12 mo. The rise with the low-GI diet was unexpected, given the stability of FPG in T2DM patients consuming a highfiber, low-GI breakfast cereal for 6 mo (20) and the sustained reduction in FPG in T2DM patients treated only with diet and acarbose (46) . Changes in FPG in T2DM patients reflect changes in hepatic glucose output (47) , which is regulated in part by insulin and FFAs (48) . We found no significant differences in plasma insulin among the diet groups, and, although mean fasting FFAs were Ȃ8% higher with the low-GI than with the high-GI diet, the difference was not significant. Nevertheless, this trend is consistent with the suggestion that low-GI diets increase fat oxidation (49) . The rise in FPG with the low-CHO diet could be related to the small rise in body weight; however, fasting insulin and FFAs in the subjects following the low-CHO diet were almost identical to the values in the subjects following the high-GI diet.
The initial reduction in plasma glucose 2 h after OGTT with the low-CHO diet is consistent with short-term studies suggesting that low-CHO diets improve insulin sensitivity in T2DM patients (50, 51) . This change is not likely to be due to a beneficial effect of MUFAs per se, because increasing MUFAs at the expense of dietary carbohydrate results in a high fat intake, and exchanging SFAs for MUFAs does not improve insulin sensitivity if total fat intake is 37% of energy (52) . Thus, the shortterm effect of a low-CHO and high-MUFA diet on insulin sensitivity in T2DM may be due to reduced glucose toxicity resulting from lower postprandial glucose responses. However, FIGURE 3. Mean (ȀSEM) body weight and diastolic blood pressure in subjects receiving the high-glycemic-index (F; n ҃ 48), low-glycemic-index (E; n ҃ 55), and low-carbohydrate (OE; n ҃ 53) diets. Values are the residuals of regression models including the baseline value and other significant confounding variables, which were as follows: A: weight, age, BMI, and center; B: diastolic blood pressure, none. The significance of the differences among diets is given in Table 4. the results in the present study suggest that low-CHO and high-MUFA meals do not continue to elicit low glycemic responses over the long term, which may explain why 2-h post-OGTT plasma glucose increased between 3 and 12 mo with the low-CHO diet.
The low-GI diet had the most favorable long-term effect on 2-h post-OGTT glucose. This finding is important, because there is good evidence both in subjects without diabetes (53) and in T2DM patients (54, 55) that high postprandial glucose is a better indicator of CVD risk than is fasting glucose. After 1 y of the low-GI diet, 2-h post-OGTT glucose concentrations were Ȃ1 mmol/L lower than those seen with the other 2 diets-a difference that, in prospective studies, was associated with a 6 -15% reduction in cardiovascular events (56, 57) . Changes in 2-h post-OGTT glucose concentrations could be due to changes in insulin sensitivity or insulin secretion or both. Short-term studies show that low-GI diets improve insulin sensitivity (58) and ␤-cell function (32, 59, 60) , and the results of the present study suggest that these effects may persist for ͧ1 y. The effects of low-GI diets on insulin sensitivity and secretion may be due directly or indirectly to reduced glycemic responses. In short-term studies in T2DM patients, the difference between the glycemic effects of low-GI and high-GI breakfast meals was quantitatively predicted by the difference in meal GI (61) . The results of the present study show that the reduced glycemic effect of high-CHO and low-GI meals is sustained and, even after 1 y, is exactly predicted by the difference in meal composition.
The major reason for concern about the use of high-CHO diets for diabetes patients is that these diets raise serum triacylglycerol and reduce HDL concentrations (16) and, hence, may increase CVD risk. However, this determination was based on the results of studies lasting 6 mo (16). The results of the present study suggest that the potentially deleterious effect of high-CHO diets on blood lipids is a temporary phenomenon lasting 6 mo. We cannot confidently assert this for serum triacylglycerol and HDL, because there were significant main effects of diet but no time ҂ diet interaction. Nevertheless, the differences in triacylglycerol and HDL between low-GI and low-CHO diets from 6 -12 mo were only Ȃ1/3 of the differences at 3 mo. In addition, triacylglycerol and HDL may not be the most relevant markers of CVD risk. Therapy of dyslipidemia to reduce CVD risk is based on targets for LDL cholesterol and total:HDL cholesterol (62) . Although we found no effect on LDL cholesterol, there was a significant time ҂ diet interaction for total:HDL cholesterol. There was a difference of Ȃ10% in total:HDL cholesterol at 3 mo, which is consistent with the results of short-term studies (44, 63) , but this difference was not present at 6, 9, and 12 mo. Because the effects of high-CHO diets on triacylglycerol and HDL-cholesterol concentrations appear to be similar in subjects with (16) and without (63) diabetes, our results may apply to more than subjects with diabetes treated with diet alone. We have no data to explain long-term adaptation, but it may be due to changes in colonic fermentation (64) or insulin sensitivity secondary to changes in body composition (65) . However, reduced adherence to the dietary treatments is not a likely explanation. The key-food diaries and 3-d food records show no change in compliance or dietary composition across the study. In addition, the significant or nearly significant time ҂ diet interactions for several variables (eg, FPG, 2-h post-OGTT glucose, and CRP), in which the differences among diets increase at the end of the study, are not consistent with reduced dietary adherence.
Our most novel finding was the larger, more sustained reduction in CRP with the low-GI diet than with the high-GI diet. The 29% difference is greater than that elicited by pravastatin in T2DM patients, ie, 13% (9) , and similar to the differences elicited by atorvastatin, ie, Ȃ25% (10), and rosiglitazone, ie, Ȃ25% (11). These findings are consistent with a prospective study showing that CRP concentrations in diabetic women were inversely related to diet GI but not to diet GL (66) . Hyperglycemia induces the release of inflammatory cytokines from monocytes (67) . Although differences in HbA 1c cannot explain the differences in CRP that we observed, differences in glucose fluctuations may be involved. Exposing endothelial cells to fluctuating glucose concentrations, rather than to the same average but constant concentration, increased oxidative stress and apoptosis (68) , and those increases, in turn, may trigger proinflammatory responses and greater release of CRP (69) . Thus, the reduction in CRP that we observed may be related to the lower postprandial glucose increments seen with the low-GI diet than with the other diets. In this context, it is of interest that the treatment of T2DM patients with repaglinide induced larger reductions in postprandial glucose and serum CRP than did treatment with glyburide, despite no difference in HbA 1c , and that this treatment also was associated with greater regression of carotid artery atherosclerosis (70) .
We conclude that, in T2DM patients treated with diet alone who have optimal glycemic control, long-term HbA 1c was not affected by altering the source or the amount of dietary carbohydrat. The deleterious effects of the high-CHO diets on total: HDL cholesterol had disappeared by 6 mo. The low-GI diet elicited sustained reductions in postprandial glucose and CRP, and, for these reasons, it may be preferred for the dietary management of T2DM.
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